Mostrar el registro sencillo del ítem

dc.contributor.authorYANEZ MENESES, LUZ FRANCY
dc.contributor.authorGajardo Carrasco, Tania Fernanda
dc.contributor.authorPérez Béssolo, Francisco Andrés
dc.contributor.authorTerraza-Aguirre, Claudia
dc.contributor.authorCampos-Mora, Mauricio
dc.contributor.authorPino Lagos, Karina
dc.date.accessioned2022-03-27T01:10:47Z
dc.date.available2022-03-27T01:10:47Z
dc.date.issued2015-06-02
dc.identifier.urihttps://repositorio.ufps.edu.co/handle/ufps/6433
dc.description.abstractIL-33 is a known member of the IL-1 cytokine superfamily classically named “atypical” due to its diverse functions. The receptor for this cytokine is the ST2 chain (or IL-1RL1), part of the IL-1R family, and the accessory chain IL-1R. ST2 can be found as both soluble and membrane-bound forms, property that explains, at least in part, its wide range of functions. IL-33 has increasingly gained our attention as a potential target to modulate immune responses. At the beginning, it was known as one of the participants during the development of allergic states and other Th2-mediated responses and it is now accepted that IL-33 contributes to Th1-driven pathologies as demonstrated in animal models of experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis, and trinitrobenzene sulfonic acid-induced experimental colitis, among others. Interestingly, current data are placing IL-33 as a novel regulator of immune tolerance by affecting regulatory T cells (Tregs); although the mechanism is not fully understood, it seems that dendritic cells and myeloid suppressor-derived cells may be cooperating in the generation and/or establishment of IL-33-mediated tolerance. Here, we review the most updated literature on IL-33, its role on T cell biology, and its impact in immune tolerance.eng
dc.format.extent8 Páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherFrontiers in Immunologyspa
dc.relation.ispartofFrontiers in Immunology ISSN: 1664-3224, 2015 vol:6 fasc: N/A págs: - , DOI:10.3389/fimmu.2015.00232
dc.rightsThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).eng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/spa
dc.sourcehttps://www.frontiersin.org/articles/10.3389/fimmu.2015.00232/fullspa
dc.titleAlarmin’ immunologists: IL-33 as a putative target for modulating T cell-dependent responseseng
dc.typeArtículo de revistaspa
dcterms.referencesSchmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005) 23:479–90. doi: 10.1016/j.immuni.2005.09.015spa
dcterms.referencesBrint EK, Xu D, Liu H, Dunne A, McKenzie AN, O’Neill LA, et al. ST2 is an inhibitor of interleukin 1 receptor and toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol (2004) 5:373–9. doi:10.1038/ni1050spa
dcterms.referencesMoussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS One (2008) 3:e3331. doi:10.1371/journal.pone.0003331spa
dcterms.referencesCayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A (2009) 106:9021–6. doi:10.1073/pnas.0812690106spa
dcterms.referencesPalmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol (2011) 7:321–9. doi:10.1038/nrrheum.2011.53spa
dcterms.referencesLiu X, Hammel M, He Y, Tainer JA, Jeng U-S, Zhang L, et al. Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci U S A (2013) 110(37):14918–23. doi:10.1073/pnas.1308651110spa
dcterms.referencesBessa J, Meyer CA, de Vera Mudry MC, Schlicht S, Smith SH, Iglesias A, et al. Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. J Autoimmun (2014) 55:33–41. doi:10.1016/j.jaut.2014.02.012spa
dcterms.referencesLefrancais E, Cayrol C. Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members. Eur Cytokine Netw (2012) 23:120–7. doi:10.1684/ecn.2012.0320spa
dcterms.referencesKakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov (2008) 7:827–40. doi:10.1038/nrd2660spa
dcterms.referencesHayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem (2007) 282:26369–80. doi:10.1074/jbc.M704916200spa
dcterms.referencesTalabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem (2009) 284:19420–6. doi:10.1074/jbc.M901744200spa
dcterms.referencesCarriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A (2007) 104(1):282–7. doi:10.1073/pnas.0606854104spa
dcterms.referencesAli S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, et al. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol (2011) 187:1609–16. doi:10.4049/jimmunol.1003080spa
dcterms.referencesMayuzumi N, Matsushima H, Takashima A. IL-33 promotes DC development in BM culture by triggering GM-CSF production. Eur J Immunol (2009) 39:3331–42. doi:10.1002/eji.200939472spa
dcterms.referencesRank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol (2009) 123:1047–54. doi:10.1016/j.jaci.2009.02.026spa
dcterms.referencesBesnard AG, Togbe D, Guillou N, Erard F, Quesniaux V, Ryffel B. IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur J Immunol (2011) 41:1675–86. doi:10.1002/eji.201041033spa
dcterms.referencesDuan L, Chen J, Zhang H, Yang H, Zhu P, Xiong A, et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T-cell responses in mice. Mol Med (2012) 18:753–61. doi:10.2119/molmed.2011.00428spa
dcterms.referencesMatta BM, Lott JM, Mathews LR, Liu Q, Rosborough BR, Blazar BR, et al. IL-33 Is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J Immunol (2014) 193:4010–20. doi:10.4049/jimmunol.1400481spa
dcterms.referencesLi M, Li Y, Liu X, Gao X, Wang Y. IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuroimmunol (2012) 247:25–31. doi:10.1016/j.jneuroim.2012.03.016spa
dcterms.referencesJiang HR, Milovanovic M, Allan D, Niedbala W, Besnard AG, Fukada SY, et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur J Immunol (2012) 42:1804–14. doi:10.1002/eji.201141947spa
dcterms.referencesPalmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum (2009) 60:738–49. doi:10.1002/art.24305spa
dcterms.referencesXu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A (2008) 105:10913–8. doi:10.1073/pnas.0801898105spa
dcterms.referencesLeung BP, Xu D, Culshaw S I, McInnes B, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol (2004) 173:145–50. doi:10.4049/jimmunol.173.1.145spa
dcterms.referencesTalabot-Ayer D, Martin P, Seemayer CA, Vigne S, Lamacchia C, Finckh A, et al. Immune-mediated experimental arthritis in IL-33 deficient mice. Cytokine (2014) 69:68–74. doi:10.1016/j.cyto.2014.05.007spa
dcterms.referencesCho KA, Suh JW, Sohn JH, Park JW, Lee H, Kang JL, et al. IL-33 induces Th17-mediated airway inflammation via mast cells in ovalbumin-challenged mice. Am J Physiol Lung Cell Mol Physiol (2012) 302:L429–40. doi:10.1152/ajplung.00252.2011spa
dcterms.referencesMiller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, et al. IL-33 reduces the development of atherosclerosis. J Exp Med (2008) 205(2):339–46. doi:10.1084/jem.20071868spa
dcterms.referencesHo LH, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol (2007) 82:1481–90. doi:10.1189/jlb.0407200spa
dcterms.referencesJunttila IS, Watson C, Kummola L, Chen X, Hu-Li J, Guo L, et al. Efficient cytokine-induced IL-13 production by mast cells requires both IL-33 and IL-3. J Allergy Clin Immunol (2013) 132:704–12. doi:10.1016/j.jaci.2013.03.033spa
dcterms.referencesBarlow JL, Peel S, Fox J, Panova V, Hardman CS, Camelo A, et al. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J Allergy Clin Immunol (2013) 132:933–41. doi:10.1016/j.jaci.2013.05.012spa
dcterms.referencesGrobeta P, Doser K, Falk W, Obermeier F, Hofmann C. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis (2012) 18:1900–9. doi:10.1002/ibd.22900spa
dcterms.referencesSchiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert EA, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature (2014) 513:564–8. doi:10.1038/nature13577spa
dcterms.referencesWasserman A, Ben-Shoshan J, Entin-Meer M, Maysel-Auslender S, Guzner-Gur H, Keren G. Interleukin-33 augments Treg cell levels: a flaw mechanism in atherosclerosis. Isr Med Assoc J (2012) 14(10):620–3.spa
dcterms.referencesBrunner SM, Schiechl G, Falk W, Schlitt HJ, Geissler EK, Fichtner-Feigl S. Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int (2011) 24:1027–39. doi:10.1111/j.1432-2277.2011.01306.xspa
dcterms.referencesYang Q, Li G, Zhu Y, Liu L, Chen E, Turnquist H, et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol (2011) 41:3351–60. doi:10.1002/eji.201141629spa
dcterms.referencesBonilla WV, Frohlich A, Senn K, Kallert S, Fernandez M, Johnson S, et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science (2012) 335:984–9. doi:10.1126/science.1215418spa
dcterms.referencesGao X, Wang X, Yang Q, Zhao X, Wen W, Li G, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol (2015) 194:438–45. doi:10.4049/jimmunol.1401344spa
dcterms.referencesAndre R, Lerouet D, Kimber I, Pinteaux E, Rothwell NJ. Regulation of expression of the novel IL-1 receptor family members in the mouse brain. J Neurochem (2005) 95:324–30. doi:10.1111/j.1471-4159.2005.03364.xspa
dcterms.referencesBorish L, Steinke JW. Interleukin-33 in asthma: how big of a role does it play? Curr Allergy Asthma Rep (2011) 11:7–11. doi:10.1007/s11882-010-0153-8spa
dcterms.referencesKouzaki H, Iijima K, Kobayashi T, O’Grady SM, Kita H. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol (2011) 186:4375–87. doi:10.4049/jimmunol.1003020spa
dcterms.referencesLouten J, Rankin AL, Li Y, Murphy EE, Beaumont M, Moon C, et al. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol (2011) 23:307–15. doi:10.1093/intimm/dxr006spa
dcterms.referencesKurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol (2008) 181:4780–90. doi:10.4049/jimmunol.181.11.8170spa
dcterms.referencesPecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood (2009) 113(7):1526–34. doi:10.1182/blood-2008-05-157818spa
dcterms.referencesImai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, et al. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci U S A (2013) 110(34):13921–6. doi:10.1073/pnas.1307321110spa
dcterms.referencesNakae S, Morita H, Ohno T, Arae K, Matsumoto K, Saito H. Role of interleukin-33 in innate-type immune cells in allergy. Allergol Int (2013) 62:13–20. doi:10.2332/allergolint.13-RAI-0538spa
dcterms.referencesYasuda K, Muto T, Kawagoe T, Matsumoto M, Sasaki Y, Matsushita K, et al. Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. Proc Natl Acad Sci U S A (2012) 109:3451–6. doi:10.1073/pnas.1201042109spa
dcterms.referencesMcCarthy DP, Richards MH, Miller SD. Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler’s virus-induced demyelinating disease. Methods Mol Biol (2012) 900:381–401. doi:10.1007/978-1-60761-720-4_19spa
dcterms.referencesGrinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med (2010) 207:1871–8. doi:10.1084/jem.20100209spa
dcterms.referencesKoreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP III, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 365:2055–66. doi:10.1056/NEJMoa1108188spa
dcterms.referencesSaadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibaul V, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med (2011) 365:2067–77. doi:10.1056/NEJMoa1105143spa
dcterms.referencesThalayasingam N. Anti-TNF therapy. Best Pract Res Clin Rheumatol (2011) 25:549–67. doi:10.1016/j.berh.2011.10.004spa
dcterms.referencesHashizume M, Tan SL, Takano J, Ohsawa K, Hasada I, Hanasaki A, et al. Tocilizumab, A humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights. Int Rev Immunol (2014) 34(3):265–79. doi:10.3109/08830185.2014.938325spa
dcterms.referencesSmolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2013) 72(4):482–92. doi:10.1136/annrheumdis-2012-202469spa
dcterms.referencesWagner V, Dullaart A, Bock A-K, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol (2006) 24:1211–7. doi:10.1038/nbt1006-1211spa
dcterms.referencesLiu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticules. Int J Cancer (2007) 120:2527–37. doi:10.1002/ijc.22709spa
dc.identifier.doihttps://doi.org/10.3389/fimmu.2015.00232
dc.publisher.placeChilespa
dc.relation.citationeditionVol. 6 No. (2015)spa
dc.relation.citationendpage8spa
dc.relation.citationissue(2015)spa
dc.relation.citationstartpage1spa
dc.relation.citationvolume6spa
dc.relation.citesGajardo Carrasco T, Morales RA, Pérez F, Terraza C, Yáñez L, Campos-Mora M and Pino-Lagos K (2015) Alarmin’ immunologists: IL-33 as a putative target for modulating T cell-dependent responses. Front. Immunol. 6:232. doi: 10.3389/fimmu.2015.00232
dc.relation.ispartofjournalFrontiers in Immunologyspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución 4.0 Internacional (CC BY 4.0)spa
dc.subject.proposaliL-33eng
dc.subject.proposalT cellseng
dc.subject.proposaltoleranceeng
dc.subject.proposalTransplantationeng
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTREVspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
Excepto si se señala otra cosa, la licencia del ítem se describe como This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).